1. Home
  2. ENTO vs PEGY Comparison

ENTO vs PEGY Comparison

Compare ENTO & PEGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • PEGY
  • Stock Information
  • Founded
  • ENTO 2014
  • PEGY 1969
  • Country
  • ENTO United States
  • PEGY United States
  • Employees
  • ENTO N/A
  • PEGY N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • PEGY Metal Fabrications
  • Sector
  • ENTO Health Care
  • PEGY Industrials
  • Exchange
  • ENTO Nasdaq
  • PEGY Nasdaq
  • Market Cap
  • ENTO 1.2M
  • PEGY 1.0M
  • IPO Year
  • ENTO 2016
  • PEGY N/A
  • Fundamental
  • Price
  • ENTO $0.62
  • PEGY $5.09
  • Analyst Decision
  • ENTO
  • PEGY
  • Analyst Count
  • ENTO 0
  • PEGY 0
  • Target Price
  • ENTO N/A
  • PEGY N/A
  • AVG Volume (30 Days)
  • ENTO 924.5K
  • PEGY 2.3M
  • Earning Date
  • ENTO 10-21-2024
  • PEGY 11-07-2024
  • Dividend Yield
  • ENTO N/A
  • PEGY N/A
  • EPS Growth
  • ENTO N/A
  • PEGY N/A
  • EPS
  • ENTO N/A
  • PEGY N/A
  • Revenue
  • ENTO N/A
  • PEGY $64,499,610.00
  • Revenue This Year
  • ENTO N/A
  • PEGY $12.33
  • Revenue Next Year
  • ENTO N/A
  • PEGY N/A
  • P/E Ratio
  • ENTO N/A
  • PEGY N/A
  • Revenue Growth
  • ENTO N/A
  • PEGY N/A
  • 52 Week Low
  • ENTO $0.19
  • PEGY $4.68
  • 52 Week High
  • ENTO $14.51
  • PEGY $735.00
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 59.35
  • PEGY 33.11
  • Support Level
  • ENTO $0.38
  • PEGY $4.68
  • Resistance Level
  • ENTO $0.87
  • PEGY $12.18
  • Average True Range (ATR)
  • ENTO 0.14
  • PEGY 1.28
  • MACD
  • ENTO 0.03
  • PEGY 1.33
  • Stochastic Oscillator
  • ENTO 52.57
  • PEGY 7.60

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About PEGY Pineapple Energy Inc.

Pineapple Energy Inc provides households with sustainable solar energy, back-up power and security, control and predictability, and cost savings. The company provides a full range of installation services, including the design, engineering, procurement, permitting, construction, grid connection, warranty, monitoring and maintenance of residential solar energy systems. It also offers battery storage to customers in select markets and serves a limited number of enterprise customers.

Share on Social Networks: